Dendritic cell vaccination after chemotherapy-induced remission in acute myeloid leukemia has a "demonstrable" anti-relapse effect for some high-risk patient, according to data presented at ASH 2013.
The novel pan-AKT inhibitor, afuresertib, demonstrated significant clinical activity when combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma, according to research at ASH 2013.
CTL019 cells can induce potent and durable responses in children and adults with relapsed/refractory acute lymphoblastic leukemia, according to results of a pilot study reported at ASH 2013.
Studies presented at the 15th World Conference on Lung Cancer reveal two new approaches to improving outcome in advanced-stage lung cancer.
Calcium, in particular, appears to have a protective benefit against lung cancer for some subgroups.
Author: Barbara Ann Burtness, MD
H.R. is a 70-year-old woman who presented to her dentist with a 2-year history of ...
Author: Sandra Puri Cuellar, PharmD, BCOP
Upon laboratory testing, SL, a 64-year-old female diagnosed with Philadephia chromosome–positive (Ph+) ALL, was ...
Dr. Farma and his colleagues present this unique case study.
Editorial Advisory Board member Mark Socinski, MD, discusses key clinical insights brought to light by the POINTBREAK trial of maintenance therapy for NSCLC.
Barbara Ann Burtness, MD
Steven Cohen, MD
E. David Crawford, MD
Don S. Dizon, MD, FACP
Jeffrey M. Farma, MD
Sergio A. Giralt, MD
Todd Morgan, MD
Edith A. Perez, MD
Neal D. Shore, MD, FACS
Mark A. Socinski, MD
Martin Tallman, MD
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|